Gum Tech sales & earnings
This article was originally published in The Tan Sheet
Executive Summary
"Growing consumer acceptance of the Zicam brand" spurred sales 17.9% to $5.5 mil. in fourth quarter, up 48.6% to $16.1 mil. for the year, Phoenix-based firm reports Feb. 28. Net loss for FY '01 improved 22.2% to $4.8 mil. Gum Tech's plans for 2002 include corporate name change, continued aggressive advertising, expanded R&D, application for CHPA membership and strengthening of senior management, firm says...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: